MELBOURNE, Australia, July 14, 2022 /PRNewswire/ -- A Qualitative Research Study accomplished by Data Bridge Market research's database of 350...
Quantitative biomarkers of demyelination can improve clinical trial design and accelerate development of disease-modifying therapeutics SAN FRANCISCO, July 14, 2022...
DURBAN, South Africa, July 14, 2022 /PRNewswire/ -- "Global Life Science Software Market" the new research report adds in Data Bridge...
BERLIN, July 14, 2022 /PRNewswire/ -- Recent study report released by Data Bridge Market research with titled "Global Total Lab Automation Market" (covering...
ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets...
NANJING, China, July 13, 2022 /PRNewswire/ -- On July 13, 2022, Triastek, Inc. ("Triastek") announced a collaboration with Eli Lilly...
WALTHAM, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...
- Horizon Platform Originates Record $192 Million of New Loans in Q2, Including $137 Million of New Loans for HRZN...
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a...
Demonstrates OBDS Device Performance and Bioavailability in Animal ModelsSAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq:...
Chiesi’s Annual and Sustainability Report 2021 is released today;Progress toward business, environmental and social targets is strong;Company is joining forces...
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance...
Los Angeles, CA, July 14, 2022 (GLOBE NEWSWIRE) -- MDbio are a leading plant-based, wellness solution who provide safe, pharmaceutical-grade...
KELOWNA, British Columbia, July 14, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two...
Strengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the...
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the...
Four new members enhance independence and diversity of Board of DirectorsAlvotech is dual listed on NASDAQ in the U.S. and...
Four new members enhance independence and diversity of Board of DirectorsAlvotech (NASDAQ and First North Growth Market: ALVO), a global...
New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects Significantly...